HomeHealth CareDrugs

Drugs

Health Care

Arcutis Wants to Be A Go-To Treatment

Howard Fine - September 25, 2024

Drugs

Amgen Drug Gets Second FDA Nod

Antonio Pequeño IV - June 20, 2022

Drugs

AskGene Lands $20 Million in Series A Round

Antonio Pequeño - May 11, 2022

Drugs

$7.1 Billion Tax Issue Eclipses Amgen’s Quarterly Performance

Joel Russell - April 28, 2022

Drugs

Fujifilm Completes Acquisition of Atara Biotherapeutics Facility

Antonio Pequeño IV - April 5, 2022

Drugs

Capsida Biotherapeutics Appoints Chief Operating Officer

Antonio Pequeño IV - March 23, 2022

Drugs

Amgen Issues ‘Green Bond’

Antonio Pequeño IV - February 23, 2022

Drugs

Amgen Quarterly Report, $6 Billion Buyback Pushes Shares Higher

Antonio Pequeño IV - February 8, 2022

Drugs

Amgen Forms Collaboration for Hard-to-Treat Diseases

Antonio Pequeño IV - February 3, 2022

Drugs

Simulations Plus to Modify Software Through Funded Partnership

Antonio Pequeño IV - January 25, 2022

Drugs

Amgen Enters Research Collaboration With Arrakis

Antonio Pequeño IV - January 14, 2022

Drugs

Acelyrin Appoints Chief Operating Officer

Antonio Pequeño IV - January 12, 2022

Drugs

Amgen and BioLabs LA Award Second Golden Ticket

Antonio Pequeño IV - January 11, 2022

Drugs

Amgen Lung Cancer Treatment Approved by European Commission

Antonio Pequeño IV - January 10, 2022

Drugs

Arcutis Biotherapeutics Obtains $225 Million in Debt Financing

Antonio Pequeño IV - December 28, 2021

Drugs

Amgen’s Otezla Receives Expanded FDA Approval for Plaque Psoriasis

Antonio Pequeño IV - December 27, 2021

Drugs

Amgen, AstraZeneca Asthma Drug Approved by FDA

Antonio Pequeño IV - December 22, 2021

Drugs

Simulations Plus Donates $25,000 for Medicine Distribution

staff-author - November 30, 2021

Drugs

Acelyrin Secures $250 Million in Financing

staff-author - November 17, 2021

Drugs

Simulations Plus Misses Estimates on Earnings in Fiscal Fourth Quarter

Joel Russell - October 25, 2021

Drugs

Amgen Finalizes Teneobio Acquisition

Antonio Pequeño IV - October 19, 2021

Drugs

MannKind Shares Fall 18 Percent on FDA Decision

Joel Russell - October 18, 2021

Drugs

Calabasas Doctor Sentenced for Rx Bribery Scheme

Antonio Pequeño IV - October 18, 2021

Drugs

Amgen Announces R&D Partnership on Brain Diseases

Antonio Pequeño IV - October 7, 2021

Join Our Membership

Drugs

Arcutis Wants to Be A Go-To Treatment

Amgen Drug Gets Second FDA Nod

AskGene Lands $20 Million in Series A Round

$7.1 Billion Tax Issue Eclipses Amgen’s Quarterly Performance

Fujifilm Completes Acquisition of Atara Biotherapeutics Facility

Capsida Biotherapeutics Appoints Chief Operating Officer

Amgen Issues ‘Green Bond’

Amgen Quarterly Report, $6 Billion Buyback Pushes Shares Higher

Amgen Forms Collaboration for Hard-to-Treat Diseases

Simulations Plus to Modify Software Through Funded Partnership

Amgen Enters Research Collaboration With Arrakis

Acelyrin Appoints Chief Operating Officer

Amgen and BioLabs LA Award Second Golden Ticket

Amgen Lung Cancer Treatment Approved by European Commission

Arcutis Biotherapeutics Obtains $225 Million in Debt Financing

Amgen’s Otezla Receives Expanded FDA Approval for Plaque Psoriasis

Amgen, AstraZeneca Asthma Drug Approved by FDA

Simulations Plus Donates $25,000 for Medicine Distribution

Acelyrin Secures $250 Million in Financing

Simulations Plus Misses Estimates on Earnings in Fiscal Fourth Quarter

Amgen Finalizes Teneobio Acquisition

MannKind Shares Fall 18 Percent on FDA Decision

Calabasas Doctor Sentenced for Rx Bribery Scheme

Amgen Announces R&D Partnership on Brain Diseases

ADVERTISE WITH US

ABOUT US

Membership Center

OTHER JOURNALS